Risk SNP-Mediated Promoter-Enhancer Switching Drives Prostate Cancer through lncRNA PCAT19

Area of Science:

• Genetics
• Molecular Biology
• Cancer Research

Background:

• Single nucleotide polymorphisms (SNPs) associated with prostate cancer (PCa) risk can influence disease aggressiveness.
• Long noncoding RNAs (lncRNAs) play critical roles in cancer development and progression.

Purpose of the Study:

• To elucidate the functional mechanism of the PCa risk SNP rs11672691 in regulating lncRNA PCAT19 expression and its impact on PCa aggressiveness.
• To investigate the role of PCAT19 isoforms in PCa progression.

Main Methods:

• SNP mapping and expression analysis of PCAT19 isoforms.
• Reporter assays to assess promoter and enhancer activity.
• Investigation of transcription factor binding and protein interactions.
• Analysis of gene expression related to cell cycle and PCa progression.

Main Results:

• The PCa risk SNP rs11672691 is located in the promoter of PCAT19-short and affects the expression of both PCAT19-short and PCAT19-long.
• The risk variant alters transcription factor binding, leading to decreased promoter activity and increased enhancer activity, thereby upregulating PCAT19-long.
• PCAT19-long interacts with HNRNPAB to activate cell-cycle genes, promoting PCa tumor growth and metastasis.

Conclusions:

• A novel risk SNP-mediated promoter-enhancer switching mechanism regulates PCAT19 isoforms.
• This mechanism contributes to both the initiation and progression of aggressive prostate cancer.
• PCAT19-long emerges as a key player in promoting PCa aggressiveness.